cagrilintide semaglutide combination cagrisema phase 3 results 2024 2025 A new drug combo of (GLP-1 receptor agonist) with (amylin analogue) failed to do as well as tirzepatide (GLP-1/GIP receptor agonist). The future of these medicines is hitting different receptors Presenters to provide first look

One critique of the SURPASS II trial is that tirzepatide was not compared to the full 2.4mg dose of semaglutide (Wegovy) approved for weight loss

Tirzepatide begins at 2.5 mg, which is increased every four weeks to a maximum of 15 mg

Water Treat

Melatonin production is stimulated in the dark

doi: 10.1530/EC-23-0005 PMID: 37159343 Pronunciation: kan-a-gli-FLOE-zin Dapagliflozin (Farxiga ) Trade Names: Farxiga (Forxiga in Europe) Drug Class: Anti-diabetic drug, Hypoglycemic, SGLT-2 inhibitor, Gliflozin Pharmacology is similar to canagliflozin, the other SGLT-2 inhibitor in this drug class Mechanism of Action: Hypoglycemic : Inhibits the Na-glucose co-transporter 2 (SGLT-2) in the kidney to reduce glucose reabsorption, resulting in increased urinary glucose excretion, and lower plasma glucose

Metabolic Disease: Insulin resistance, obesity, and T2D research via AMPK and mitochondrial pathway modulation